Travere Therapeutics, Inc. (NASDAQ: TVTX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.53 | Insider Own | 2.30% | Shs Outstand | 92.99M | Perf Week | 9.72% |
| Market Cap | 5.70B | Forward P/E | 19.40 | EPS next Y | 3.16 | Insider Trans | -22.80% | Shs Float | 90.37M | Perf Month | 4.87% |
| Enterprise Value | 6.20B | PEG | 1.19 | EPS next Q | - | Inst Own | - | Short Float | 13.30% | Perf Quarter | 43.74% |
| Income | -43.34M | P/S | 9.64 | EPS this Y | 93.91% | Inst Trans | - | Short Ratio | 5.36 | Perf Half Y | 108.08% |
| Sales | 591.33M | P/B | - | EPS next Y | 9888.54% | ROA | -5.44% | Short Interest | 12.02M | Perf YTD | 60.48% |
| Book/sh | - | P/C | 109.53 | EPS next 5Y | - | ROE | -55.79% | 52W High | 66.73 -7.43% | Perf Year | 255.68% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -6.19% | 52W Low | 15.71 293.08% | Perf 3Y | 268.95% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 65.15% 19.92% | Gross Margin | 94.41% | Volatility | 5.73% 4.90% | Perf 5Y | 345.96% |
| Dividend TTM | - | EV/Sales | 10.49 | EPS Y/Y TTM | 87.01% | Oper. Margin | -6.84% | ATR (14) | 3.04 | Perf 10Y | 249.80% |
| Dividend Ex-Date | - | Quick Ratio | 3.99 | Sales Y/Y TTM | 130.04% | Profit Margin | -7.35% | RSI (14) | 63.59 | Recom | 2.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.05 | EPS Q/Q | 17.02% | SMA20 | 7.27% | Beta | 1.01 | Target Price | 62.75 |
| Payout | 0.00% | Debt/Eq | 25.16 | Sales Q/Q | 54.88% | SMA50 | 12.43% | Rel Volume | 0.63 | Prev Close | 61.32 |
| Employees | 497 | LT Debt/Eq | 2.81 | Earnings | Oct 29 | SMA200 | 56.55% | Avg Volume | 1.96M | Price | 61.77 |
| IPO Date | Nov 08, 2012 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -61.14% -6.63% | Net Debt/EBITDA | 323.30 | Volume | 1,226,232 | Change | 0.73% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-06-26 | Reiterated | Canaccord Genuity | Buy | $62 → $70 |
| Jun-25-26 | Reiterated | Guggenheim | Buy | $54 → $65 |
| Jun-02-26 | Reiterated | HC Wainwright & Co. | Buy | $18 → $67 |
| Apr-14-26 | Reiterated | Piper Sandler | Neutral | $12 → $49 |
| Apr-14-26 | Reiterated | Guggenheim | Buy | $49 → $54 |
| Jan-14-26 | Reiterated | Guggenheim | Buy | $23 → $49 |
| Sep-10-25 | Reiterated | Jefferies | $35 | |
| Oct-31-24 | Reiterated | Evercore ISI | Outperform | $30 → $33 |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight | $28 → $27 |
| Oct-10-24 | Reiterated | Evercore ISI | Outperform | $12 → $30 |
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 592 | 491 | 233 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 34 | 10 | 8 | — | — | — | — | — | — | |
| Gross Profit | 557 | 480 | 225 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 364 | 337 | 264 | — | — | — | — | — | — | |
| Research and Development | 227 | 206 | 283 | — | — | — | — | — | — | |
| Other Operating Expense | 7 | 0 | 2 | — | — | — | — | — | — | |
| Operating Income | -40 | -63 | -324 | — | — | — | — | — | — | |
| Interest Expense | 9 | 11 | 11 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -17 | 24 | 14 | — | — | — | — | — | — | |
| Net Income Before Taxes | -67 | -49 | -321 | — | — | — | — | — | — | |
| Income Taxes | 1 | 1 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -43 | -26 | -322 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -68 | -50 | -321 | — | — | — | — | — | — | |
| Net Income | -43 | -26 | -322 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.45 | -0.56 | -4.08 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.45 | -0.56 | -4.08 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.49 | -0.56 | -4.08 | — | — | — | — | — | — | |
| EBITDA | 1 | 22 | -266 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 9.70 | 6.93 | 5.91 | — | — | — | — | — | — | |
| Gross Margin | 94.09 | 97.76 | 96.57 | — | — | — | — | — | — | |
| Operating Margin | -6.76 | -12.83 | -139.06 | — | — | — | — | — | — | |
| Net Margin | -7.26 | -5.30 | -138.20 | — | — | — | — | — | — | |
| Shares Outstanding | 93 | 89 | 79 | — | — | — | — | — | — | |
| Market Capitalization | 5,745 | 3,401 | 1,376 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Coughlin Timothy | Director | Jun 12 '26 | Sale | 50.07 | 10,000 | 500,747 | 56,250 | Jun 16 |
| Baynes Roy D. | Director | Jun 12 '26 | Option Exercise | 21.38 | 4,500 | 96,210 | 46,000 | Jun 16 |
| Baynes Roy D. | Director | Jun 12 '26 | Sale | 50.00 | 4,500 | 225,000 | 41,500 | Jun 16 |
| Coughlin Timothy | Director | Jun 12 '26 | Option Exercise | 26.52 | 10,000 | 265,200 | 66,250 | Jun 16 |
| Coughlin Timothy | Director | May 15 '26 | Sale | 43.49 | 3,250 | 141,343 | 52,250 | May 19 |
| REED ELIZABETH E | Chief Legal Officer and GC | May 06 '26 | Sale | 43.95 | 2,076 | 91,240 | 105,211 | May 06 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | May 06 '26 | Sale | 43.95 | 22,500 | 988,875 | 432,886 | May 06 |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | May 06 '26 | Sale | 43.95 | 310 | 13,625 | 118,658 | May 06 |
| Inrig Jula | CHIEF MEDICAL OFFICER | May 06 '26 | Sale | 43.95 | 311 | 13,668 | 113,238 | May 06 |
| ROTE WILLIAM E. | Chief Research Officer | May 06 '26 | Sale | 43.95 | 2,763 | 121,434 | 115,474 | May 06 |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | May 05 '26 | Sale | 46.65 | 2,181 | 101,744 | 118,968 | May 06 |
| Inrig Jula | CHIEF MEDICAL OFFICER | May 05 '26 | Sale | 46.65 | 2,174 | 101,417 | 113,549 | May 06 |
| Baynes Roy D. | Director | May 05 '26 | Sale | 46.65 | 4,500 | 209,925 | 37,500 | May 06 |
| Baynes Roy D. | Director | May 05 '26 | Option Exercise | 18.27 | 4,500 | 82,215 | 42,000 | May 06 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER | May 05 '26 | Sale | 46.65 | 2,174 | 101,417 | 140,684 | May 06 |